Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sector perform” rating reissued by equities researchers at Royal Bank of Canada in a note issued to investors on Tuesday, MarketBeat reports. They currently have a $142.00 price target on the biotechnology company’s stock, down from their prior price target of $157.00. Royal Bank of […]
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month […]
Clearbridge Investments LLC Buys New Shares in Sarepta Therapeutics, Inc (NASDAQ:SRPT) modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a research note issued on Monday, Benzinga reports. They presently have a $166.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price objective would suggest a potential upside of 28.56% from the company’s […]
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its target price hoisted by Mizuho from $145.00 to $179.00 in a report issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Mizuho’s target price would suggest a potential upside of 36.25% from the stock’s previous close. A number […]